Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.

Gillooly KM, Pulicicchio C, Pattoli MA, Cheng L, Skala S, Heimrich EM, McIntyre KW, Taylor TL, Kukral DW, Dudhgaonkar S, Nagar J, Banas D, Watterson SH, Tino JA, Fura A, Burke JR.

PLoS One. 2017 Jul 24;12(7):e0181782. doi: 10.1371/journal.pone.0181782. eCollection 2017.

2.

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.

Ma Z, Liu X, Xu X, Jiang J, Zhou J, Wang J, Chen D, Luo S.

Medicine (Baltimore). 2017 Jun;96(25):e7145. doi: 10.1097/MD.0000000000007145. Review.

3.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

4.

Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.

Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM.

World J Hepatol. 2017 May 8;9(13):613-626. doi: 10.4254/wjh.v9.i13.613. Review.

5.

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.

Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M.

World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):131-136. doi: 10.4292/wjgpt.v8.i2.131.

6.

Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.

Araki Y, Mimura T.

Int J Mol Sci. 2017 Apr 25;18(5). pii: E905. doi: 10.3390/ijms18050905. Review.

7.

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.

Dénarié D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H.

Mediators Inflamm. 2017;2017:3708250. doi: 10.1155/2017/3708250. Epub 2017 Mar 2.

8.

Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M.

BMJ Open. 2017 Mar 22;7(3):e012567. doi: 10.1136/bmjopen-2016-012567.

9.

Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.

Fleischmann R, Tongbram V, van Vollenhoven R, Tang DH, Chung J, Collier D, Urs S, Ndirangu K, Wells G, Pope J.

RMD Open. 2017 Jan 3;3(1):e000371. doi: 10.1136/rmdopen-2016-000371. eCollection 2017.

10.

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K; BSRBR-RA*; BSRBR-RA Control Centre Consortium*, Symmons DP, Hyrich KL.

RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017. Erratum in: RMD Open. 2017 Feb 23;3(1):e000314corr1.

11.

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.

Smolen JS, Agarwal SK, Ilivanova E, Xu XL, Miao Y, Zhuang Y, Nnane I, Radziszewski W, Greenspan A, Beutler A, Baker D.

Ann Rheum Dis. 2017 May;76(5):831-839. doi: 10.1136/annrheumdis-2016-209831. Epub 2017 Jan 13.

12.

CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss.

Collins FL, Williams JO, Bloom AC, Singh RK, Jordan L, Stone MD, McCabe LR, Wang EC, Williams AS.

Bone. 2017 Apr;97:94-104. doi: 10.1016/j.bone.2017.01.002. Epub 2017 Jan 4.

13.

A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.

Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Wallman JK, Ernestam S, Bolce RJ, van Vollenhoven RF.

Arthritis Rheumatol. 2017 May;69(5):953-963. doi: 10.1002/art.40019. Epub 2017 Mar 31.

14.

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.

Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.

Arthritis Res Ther. 2016 Dec 1;18(1):280.

15.

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?

Humphreys J, Hyrich K, Symmons D.

Arthritis Res Ther. 2016 Dec 1;18(1):282. Review.

16.

Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis.

Park MJ, Lee SH, Moon SJ, Lee JA, Lee EJ, Kim EK, Park JS, Lee J, Min JK, Kim SJ, Park SH, Cho ML.

Sci Rep. 2016 Nov 2;6:35933. doi: 10.1038/srep35933.

18.

New and emerging therapies for the treatment of rheumatoid arthritis.

Feely MG.

Open Access Rheumatol. 2010 Jul 24;2:35-43. eCollection 2010. Review.

20.

Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions.

Tiwari A, Luo H, Chen X, Singh P, Bhattacharya I, Jasper P, Tolsma JE, Jones HM, Zutshi A, Abraham AK.

CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):565-574. doi: 10.1002/psp4.12126. Epub 2016 Oct 22.

Supplemental Content

Support Center